Tranilast, an antifibrotic agent and COVID-19-induced pulmonary fibrosis.
作者信息
Oshitani N, Watanabe K, Sakuma T, Matsuda M, Oyama Y
机构信息
Department of Internal Medicine, Social Welfare Service Corporation Ishii Memorial Aizen-en, Aizenbashi Infirmary, Osaka, Japan.
Department of Radiology, Social Welfare Service Corporation Ishii Memorial Aizen-en, Aizenbashi Infirmary, Osaka, Japan.
出版信息
QJM. 2022 Apr 20;115(4):249-250. doi: 10.1093/qjmed/hcac069.
Abstract
摘要
相似文献
1
Tranilast, an antifibrotic agent and COVID-19-induced pulmonary fibrosis.
QJM. 2022 Apr 20;115(4):249-250. doi: 10.1093/qjmed/hcac069.
2
Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis.
Jpn J Pharmacol. 1995 Apr;67(4):279-89. doi: 10.1254/jjp.67.279.
3
Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit.
Int Immunopharmacol. 2024 Aug 20;137:112423. doi: 10.1016/j.intimp.2024.112423. Epub 2024 Jun 10.
4
Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis.
Int Arch Allergy Appl Immunol. 1991;95(2-3):195-201. doi: 10.1159/000235429.
5
Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta.
Cardiovasc Res. 2005 Feb 15;65(3):694-701. doi: 10.1016/j.cardiores.2004.10.041.
6
Effect of tranilast on myocardial fibrosis in diabetes rats through TGF-β/Smad pathway.
Minerva Med. 2021 Feb;112(1):153-154. doi: 10.23736/S0026-4806.19.06178-0. Epub 2019 Jul 9.
7
Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction.
Heart Lung Circ. 2013 Feb;22(2):122-32. doi: 10.1016/j.hlc.2012.08.054. Epub 2012 Sep 15.
8
Tranilast: a review of its therapeutic applications.
Pharmacol Res. 2015 Jan;91:15-28. doi: 10.1016/j.phrs.2014.10.009. Epub 2014 Nov 10.
9
COVID-related fibrosis: insights into potential drug targets.
Expert Opin Investig Drugs. 2021 Dec;30(12):1183-1195. doi: 10.1080/13543784.2021.2010188. Epub 2021 Dec 1.
10
Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
Nephron Physiol. 2003;95(4):p83-91. doi: 10.1159/000074845.
引用本文的文献
1
Pulmonary fibrosis through the prism of NLRP3 inflammasome: mechanistic pathways and prospective therapeutic innovations.
Front Immunol. 2025 May 5;16:1593729. doi: 10.3389/fimmu.2025.1593729. eCollection 2025.
2
Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers.
Int J Mol Sci. 2024 Jan 26;25(3):1562. doi: 10.3390/ijms25031562.
本文引用的文献
1
Severe organising pneumonia following COVID-19.
Thorax. 2021 Feb;76(2):201-204. doi: 10.1136/thoraxjnl-2020-216088. Epub 2020 Nov 11.
2
Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease.
Gut. 2007 Apr;56(4):599-600. doi: 10.1136/gut.2006.115469.
3
Effect of tranilast on matrix metalloproteinase production from neutrophils in-vitro.
J Pharm Pharmacol. 2006 Jan;58(1):91-9. doi: 10.1211/jpp.58.1.0011.
4
Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta.
Cardiovasc Res. 2005 Feb 15;65(3):694-701. doi: 10.1016/j.cardiores.2004.10.041.
5
Anti-allergic agent tranilast decreases development of obliterative airway disease in rat model of heterotopic tracheal transplantation.
J Heart Lung Transplant. 2004 Dec;23(12):1392-5. doi: 10.1016/j.healun.2003.09.020.
Zotero 插件